Table 2.
Incidence of HF death and sudden cardiac death during pimobendan treatment of DCM mice
| Pimobendan (mg·kg-1·day−1) | ||||||
|---|---|---|---|---|---|---|
| Compensated HF | End-stage HF | |||||
| 0 (vehicle) | 10 | 100 | 0 (vehicle) | 10 | 100 | |
| Number of mice | 6 | 6 | 6 | 5 | 5 | 5 |
| Maximum treatment period (days) | 37 | 84 | 84 | 8 | 38 | 23 |
| Number of all-cause deaths | 6 | 5 | 1 | 5 | 5 | 5 |
| Number of HF deaths | 6 | 5 | 0 | 5 | 5 | 0 |
| Number of sudden cardiac deaths | 0 | 0 | 1 | 0 | 0 | 5 |
Deaths after progressive decreases in body weight and temperature were considered to be HF death, while deaths despite preservation or recovery of body weight and temperature were considered to be sudden cardiac death.